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Liver Lesion Characterization: The 
Wrong Choice of Contrast Agent Can 
Mislead the Diagnosis of Hemangioma
Over the past few years, abdominal radiol-
ogy experts studying the liver have increased 
the usage of liver-specific gadolinium-chelate 
contrast agents. These agents are gadobenate 
dimeglumine (MultiHance, Bracco) and gad-
oxetate (Primovist, Bayer HealthCare), with 
different biliary rate excretion (5% and 50%) 
and liver-specific phase acquisition time (120 
and 20 minutes), respectively.
This great difference in biliary clearance 
requires the radiologist’s consideration, es-
pecially in the study of focal lesions. In fact, 
with Primovist, the equilibrium phase (180 
seconds) is an early-uptake stage because of 
the quick accumulation of the contrast agent 
in hepatic cells. Therefore, we must consider 
a false washout at the equilibrium phase, in 
which Primovist is retained in the hemangio-
ma, which nonetheless appears iso- or hypo-
intense on T1-weighted images because of the 
increasing signal intensity of the surrounding 
healthy hepatic parenchyma. This implies that 
hemangiomas may have a misleading contrast 
imaging pattern with Primovist, without the 
usual, well-demonstrable fill in, as assessed 
by Gupta et al. [1] who showed the different 
contrast imaging pattern of hemangiomas with 
Primovist and MultiHance.
This nontypical pattern of hemangiomas 
with Primovist does not represent a significant 
problem in detecting large masses, which 
are already well recognizable on unenhanced 
acquisitions. However, it can be difficult to 
properly characterize small lesions that may not 
be benign [2]. In particular, it can be compli-
cated when we observe small multiple heman-
giomas—sometimes with a prevalent fibrous 
component and relatively low signal intensity 
in heavily T2-weighted acquisitions—that have 
not been documented in previous examinations 
or, as often occurs in daily practice, in patients 
lacking an accurate clinical history or previous 
examination (e.g., occasional hepatic lesion 
seen on an ultrasound examination) (Fig. 1).
These problems can be amplified if, to opti-
mize examination time, the radiologist chooses 
to apply the Primovist inverse study protocol, 
in which only the T1-weighted sequences are 
acquired before the dynamic phase, and T2-
weighted and diffusion-weighted sequences 
are acquired in the contrast-enhanced phase 
before the hepatobiliary phase is acquired. 
Such an inverse modality is based on stud-
ies that have highlighted that Primovist does 
not influence the T2-weighted and diffusion-
weighted sequences, and our experience con-
firms these data [3].
Of course, the saving in time is relevant, 
but the risk of selecting an unsuitable con-
trast agent is increased. On the basis of these 
considerations, to avoid the risk of making 
mistakes or at least to deal with divergent 
patterns in patients without a clinical history 
or with a suspicion of hemangioma, we pre-
fer the use of MultiHance, which can act as 
a non–liver-specific gadolinium chelate (with 
an appropriate dynamic phase) and, if neces-
sary, make it possible to acquire a hepato-
biliary phase.
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Fig. 1—44-year-old woman with no history of malignancy who presented with multiple small hepatic lesions.
A and B, T1-weighted images (A) show two small hypointense lesions that appear hyperintense on T2-weighted 
images (B) with TE of 320 ms.
C and D, T1-weighted images obtained 3 minutes after administration of gadoxetate (C) and T1-weighted 
images obtained 3 minutes after injection of gadobenate dimeglumine (D). In case of small angiomas, as in this 
patient, use of gadoxetate can confuse, causing diagnosis of malignancy.
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